drugset
drugset / Trial / NCT01964651

Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of JNJ-42165279 in Healthy Young and Elderly Participants

NCT01964651 ↗

Phase 1 Completed 40 enrolled Janssen Research & Development, LLC
RandomizedParallel-groupDouble-blindTreatment

Summary

The purpose of this study is to assess the safety, tolerability, and pharmacokinetics of JNJ-42165279 in healthy, young and elderly, male and female participants after repeated oral dose administration.

Timeline

Start
2013-10
Primary completion
2014-10
Completion
2014-10

Drugs

EvaluationDrugModalityDoseRoute
Subject JNJ-42165279 Small molecule 30 mg Oral
Subject JNJ-42165279 Small molecule 50 mg Oral
Subject JNJ-42165279 Small molecule 100 mg Oral

Indications

No indication recorded.